Episode

IV Iron Risks and Low-Dose AML Gains

Podcast
Blood Podcast
Published
Jul 2, 2026
Duration seconds
1488
Processing state
not_requested
Canonical source
https://share.transistor.fm/s/c7970701
Audio
https://prfx.byspotify.com/e/media.transistor.fm/c7970701/0ccda55d.mp3
JSON
/v1/public/podcasts/blood-podcast-664776/episodes/iv-iron-risks-and-low-dose-aml-gains
Markdown
/podcast/blood-podcast-664776/iv-iron-risks-and-low-dose-aml-gains.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/iv-iron-risks-and-low-dose-aml-gains/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/blood-podcast-664776/iv-iron-risks-and-low-dose-aml-gains.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood . Dr. Zoller discusses " Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia ", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications. Dr. Ribeiro discusses " A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial " and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.